JPMorgan sees shares of Ultragenyx Pharmaceutical soaring more than 200% from current prices.
Get this delivered to your inbox, and more info about our products and services.
The cohort could be better positioned to navigate headwinds including tariffs than previously thought.
The investment bank upgraded the pharma stock to overweight from equal weight.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
Based on its 12-month price target, Mizuho sees shares of Vaxcyte soaring almost 300% from current levels.
Alphabet and Allstate are among the firm's top ideas for a year in which AI will continue to drive the market.
JPMorgan analyst Doug Anmuth believes that the AI theme will continue to "drive continued outperformance in Quality Growth,…
